BioCryst Pharmaceuticals Inc (BCRX) Insider Trading
- $10,010,216.84
- $40,804,433.76
- June 15, 2023
- Thomas R Staab II
Trader Name | Date | Title | Amount | Price | Type | Total Value |
---|---|---|---|---|---|---|
June 15, 2023 | Director | 4,000 | $7.98 | Sell | $31,920.00 | |
Feb. 1, 2023 | CEO | 100,000 | $10.38 | Sell | $1,038,000.00 | |
Dec. 15, 2022 | CFO | 5,700 | $10.90 | Sell | $62,130.00 | |
Dec. 15, 2022 | Insider | 3,125 | $10.89 | Sell | $34,031.25 | |
Dec. 15, 2022 | Director | 445 | $10.90 | Sell | $4,850.50 | |
Dec. 15, 2022 | CEO | 14,100 | $10.90 | Sell | $153,690.00 | |
Dec. 2, 2022 | CEO | 82,656 | $12.80 | Sell | $1,057,996.80 | |
Dec. 1, 2022 | Director | 8,600 | $13.01 | Sell | $111,886.00 | |
Nov. 14, 2022 | Insider | 31,515 | $13.88 | Sell | $437,428.20 | |
April 1, 2022 | Insider | 7,600 | $16.20 | Sell | $123,120.00 | |
Feb. 15, 2022 | Director | 5,000 | $18.50 | Sell | $92,500.00 | |
Jan. 11, 2022 | CEO | 184,000 | $15.04 | Sell | $2,767,360.00 | |
Dec. 7, 2021 | Insider | 30,100 | $12.20 | Sell | $367,220.00 | |
Nov. 24, 2021 | Director | 7,500 | $12.19 | Buy | $91,425.00 | |
Nov. 23, 2021 | CFO | 35,258 | $12.48 | Buy | $440,019.84 | |
Nov. 15, 2021 | Director | 5,000 | $12.27 | Sell | $61,350.00 | |
Oct. 15, 2021 | Director | 105,000 | $15.40 | Sell | $1,617,000.00 | |
Sept. 10, 2021 | Director | 74,000 | $15.09 | Sell | $1,116,660.00 | |
July 15, 2021 | Director | 5,000 | $15.69 | Sell | $78,450.00 | |
May 27, 2021 | Insider | 71,759 | $15.00 | Sell | $1,076,385.00 | |
May 24, 2021 | Director | 6,667 | $13.90 | Sell | $92,671.30 | |
May 10, 2021 | Director | 7,000 | $12.70 | Sell | $88,900.00 | |
Dec. 11, 2020 | VP | 13,741 | $7.96 | Sell | $109,378.36 | |
Dec. 4, 2020 | VP | 13,741 | $6.23 | Sell | $85,606.43 | |
Aug. 11, 2020 | CFO | 54,000 | $4.08 | Buy | $220,320.00 | |
Nov. 18, 2019 | CEO | 50,000 | $1.45 | Buy | $72,500.00 | |
Nov. 18, 2019 | VP | 20,000 | $1.45 | Buy | $29,000.00 | |
Nov. 18, 2019 | Insider | 45,000 | $1.45 | Buy | $65,250.00 | |
Nov. 18, 2019 | Director | 5,000 | $1.45 | Buy | $7,250.00 | |
May 22, 2019 | Director | 3,000 | $3.57 | Buy | $10,710.00 | |
May 17, 2019 | Insider | 9,750 | $7.65 | Sell | $74,587.50 | |
May 15, 2019 | Insider | 11,750 | $7.81 | Sell | $91,767.50 | |
May 13, 2019 | Insider | 19,500 | $7.70 | Sell | $150,150.00 | |
May 9, 2019 | CFO | 9,750 | $7.63 | Sell | $74,392.50 | |
May 6, 2019 | CFO | 9,000 | $7.75 | Sell | $69,750.00 | |
May 2, 2019 | CFO | 7,750 | $7.30 | Sell | $56,575.00 | |
April 4, 2019 | Insider | 7,500 | $8.81 | Sell | $66,075.00 | |
March 12, 2019 | Director | 2,000 | $8.30 | Buy | $16,600.00 | |
Jan. 28, 2019 | CFO | 5,000 | $9.85 | Sell | $49,250.00 | |
Jan. 28, 2019 | VP | 12,000 | $9.75 | Sell | $117,000.00 | |
Jan. 25, 2019 | VP | 6,000 | $9.60 | Sell | $57,600.00 | |
Jan. 18, 2019 | VP | 2,000 | $9.40 | Sell | $18,800.00 | |
Jan. 16, 2019 | VP | 3,046 | $9.27 | Sell | $28,236.42 | |
Jan. 14, 2019 | VP | 954 | $9.20 | Sell | $8,776.80 | |
Dec. 18, 2018 | CMO | 20,488 | $7.58 | Sell | $155,299.04 | |
Dec. 10, 2018 | VP | 4,000 | $9.06 | Sell | $36,240.00 | |
Dec. 4, 2018 | Insider | 3,922 | $9.45 | Sell | $37,062.90 | |
Nov. 30, 2018 | VP | 44,290 | $9.07 | Sell | $401,710.30 | |
Nov. 23, 2018 | Insider | 15,500 | $9.32 | Sell | $144,460.00 | |
Nov. 20, 2018 | VP | 15,470 | $8.55 | Sell | $132,268.50 |
Insiders are both buying and selling BioCryst Pharmaceuticals Inc stock.
The insider traders at BioCryst Pharmaceuticals Inc are: Thomas R Staab II, Lynne Powell, William P Sheridan, Yarlagadda S Babu, Bros. Advisors Lp Baker, George B Abercrombie, Jon P Stonehouse, Alane P Barnes, Anthony Doyle, Helen M Thackray, Michael L Jones, Nancy J Hutson, Steve Aselage, Machelle Sanders, Megan Sniecinski, George Abercrombie, Vincent Milano, Peder Jensen, George B. Abercrombie, Felix Baker, Thomas Staab II, Kenneth B Lee Jr, Kenneth Lee, Jr., and Fred E Cohen
The most active insider trader at BioCryst Pharmaceuticals Inc is Thomas R Staab II with 35 trades.
Bros. Advisors Lp Baker has sold the most BioCryst Pharmaceuticals Inc stock with a total value of $40,465,900.00.
Felix Baker has bought the most BioCryst Pharmaceuticals Inc stock with a total value of $10,000,003.20.
The most recent insider trade for BioCryst Pharmaceuticals Inc was on June 15, 2023.
The single biggest insider buy for BioCryst Pharmaceuticals Inc was from Felix Baker with a total value of $5,000,001.60 on Aug. 1, 2013.
The single biggest insider sell for BioCryst Pharmaceuticals Inc was from Bros. Advisors Lp Baker with a total value of $20,232,950.00 on Aug. 16, 2016.